November 4, 2025– La Chaussée-Saint-Victor (France) – Today, the biopharmaceutical group Chiesi, a major player in the treatment of respiratory diseases, inaugurated the expansion of its industrial site located in La Chaussée-Saint-Victor, near Blois, in France.

For Chiesi, improving patient health and protecting the environment are consistent commitments embedded in the company’s strategy. Since 2019, Chiesi has invested more than 400 million euros in the research and development of its Carbon Minimal Inhalers (CMI) platform – pressurized Metered Dose Inhalers using next generation propellants ensuring up to a 90% reduction in carbon footprint per devices. The transition towards the Carbon Minimal Inhaler platform aims at delivering inhalers with comparable safety[1], efficacy, and usability, while minimizing their carbon emissions, and enabling a seamless transition for patients and tangible benefits for the planet.

The newly expanded facility in La Chaussée-Saint-Victor will serve as the manufacturing hub for this new generation of Metered Dose Inhalers, supporting Chiesi’s ambition to make sustainable respiratory treatments available worldwide.

Attending a ceremony at the site today, Maria Paola Chiesi, Chiesi Group Vice Chair, commented: “This inauguration represents much more than an industrial success. It illustrates our commitment to creating an environment where everyone contributes to a common goal: innovating for the well-being of the patients and the communities we serve, while safeguarding our planet. Every day, we act to have a positive impact on patients, communities, and the environment. This is integral to our vision of the company’s role within society.”

This new phase marks another step in Chiesi’s continuous investment towards a more sustainable and resilient supply chain. Over the past decade, Chiesi has invested more than 160 million euros on its French centre of excellence, expanding capacity to meet rising global demand, and accelerating the site's ecological transition towards more environmentally friendly processes. Now, this investment is expected to generate around 50 new direct and indirect jobs in the coming months, with the ambition of reaching 300 employees by 2026.

According to a recent economic study[2] by BDO, commissioned by Chiesi France, Chiesi generates €150 million in wealth (GDP) in France and supports 1,350 jobs – direct and indirect – the majority of which are linked to the industrial site in La Chaussée-Saint-Victor. Today, more than 80% of production is dedicated to export, with Chiesi thus making a positive contribution to France's competitiveness and international industrial influence.

Concluding, Maria Paola Chiesi added: "Europe has all the assets to succeed: scientific and manufacturing expertise, exceptional talent, and a long tradition of excellence in public health. Here, in La Chaussée-Saint-Victor, we demonstrate that Europe can not only participate in this global transformation towards sustainable development but also lead it. To achieve this, Europe must offer an environment worthy of its ambitions—one that attracts investments, accelerates transformation, and ensures equitable access to innovation for all."

******

About Chiesi Group

Chiesi is a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment.

By adopting the legal form of Benefit Corporation in Italy, the US, France and Colombia, Chiesi’s commitment to creating shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, Chiesi is part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035.

With 90 years of experience, Chiesi is headquartered in Parma (Italy), with 31 affiliates worldwide, and counts more than 7,500 employees. The Group’s research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden.

For further information please visit www.chiesi.com

******

Press Info:

Anna Bonisoli Alquati, Head of Global External Communications: mediarelations@chiesi.com

Michela Lijoi, Global External Communications Sr. Manager: mobile +39 328.6353044, e-mail: m.lijoi@chiesi.com

Davide Paterlini, Global External Communications Sr. Manager: mobile +39 345.7983132, e-mail: d.paterlini@chiesi.com

[1]  Salvadori M. et al. 2025, Pulmonary Pharmacology & Therapeutics: The low global warming potential propellant HFA-152a does not induce bronchoconstriction or impair mucociliary clearance.

Rony F. et al. 2024, Pulmonary Pharmacology & Therapeutics:  Evaluating the pharmacokinetics of beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide delivered via pressurized  metered-dose inhaler using a low global warming potential propellant.

Roche N. et al. 2024, JAMP: Pharmaceutical, clinical, and regulatory challenges of reformulating pressurized metered-dose inhalers to reduce their environmental impact.

[2] Contribution économique et sociale de Chiesi France SAS, étude économique réalisée par BDO, September 2025.